Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

<div>Patients’ disposition and primary reason for discontinuation (pooled data from ADAPT-1 and ADAPT-2, all randomized patients). AE = adverse event; EC = entry criteria; LTFU = lost to follow-up; SC = patients’ choice; WC = withdrawn consent.</div>

International Journal of Hepatology

fig1

Figure 1

Figure 1: Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies 

Figure 1 | Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies 